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Open acAbstract Background: Risk estimates for proven non-carriers in BRCAmutation families are
inconsistent for breast cancer and lacking for ovarian cancer. We aimed to assess the age-
related risks for breast and ovarian cancer for proven non-carriers in these families.
Methods: A consecutive cohort study ascertained 464 proven non-carriers who had a ﬁrst-
degree relative with a pathogenic BRCA mutation. Kaplan–Meier analyses were used to esti-
mate the age-related cancer risks, and we calculated standardised incidence ratios.
Results: In the 464 non-carriers, 17 breast cancers and two ovarian cancers were detected at a
mean age of 47 years (95% conﬁdence interval (CI) 32–61) and 49 years (95% CI 32–67),
respectively. Overall, by the age of 50, the breast and ovarian cancer risks among non-carriers
were 6.4% (95% CI 2.9–9.8%) and 0.4% (95% CI 0–1.3%), of which the breast cancer risk was
statistically signiﬁcantly higher than the risk in the general population. In particular, the num-
ber of breast cancers among non-carriers in BRCA1 families was higher than expected for the
general population (standardised incidence ratio (SIR) 2.0, 95% CI 1.1–3.3). In the BRCA1
cohort, the mean number of breast cancer cases was higher in families in which non-carriers
were diagnosed before the age of 50 (p = 0.04).
Conclusion: The age at diagnosis of breast cancer in non-carriers in BRCAmutation families is
younger than expected, yielding an increased risk in the ﬁfth decade. This effect is most evi-
dent in BRCA1 families. If our results are conﬁrmed by others, this could affect the advice
given on breast cancer screening to proven non-carriers between the age of 40 and 50 in such
families.
 2013 Elsevier Ltd. Open access under the Elsevier OA license.18
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Female carriers of a pathogenic mutation in the
BRCA1/2 genes have a high risk of developing breast
and ovarian cancer: lifetime risks range from 45% to
88% and 11% to 59%, respectively.1–6 Carriers are there-
fore enrolled in an intensive screening program and may
opt to have preventive surgery. In the Netherlands, this
program runs from the age of 25–60 years and consists
of an annual physical examination, annual breast MRI
and, from the age of 30, annual mammography.7 There
is no screening program for ovarian cancer, but BRCA1/2
mutation carriers from the age of 35–40 may opt for
risk-reducing salpingo-oophorectomy (RRSO).
It has been assumed that women who tested negative
for their family-speciﬁc BRCA mutation were not at an
increased risk.8–11 They are dismissed from intensive
screening and referred to our national breast cancer
screening program, which consists of biennial mammog-
raphy from the age of 50–75 years. However, the cancer
risk of these proven non-carriers in BRCA-positive fam-
ilies is under debate12 and several studies have published
contradictory results on their residual breast cancer
risk.8–11,13–16 The reported risk ratios ranges from 0.39
to 5.3, while there are no ﬁgures available for residual
ovarian cancer risk.
It is thus uncertain whether non-carriers in BRCA-
positive families are rightly being advised to stop screen-
ing and to wait until they can enrol in the national pro-
gram, and we do not know what advice to give them
regarding their possible ovarian cancer risk. Our aim
was to evaluate the breast and ovarian cancer risks for
proven non-carriers who have a ﬁrst-degree relative with
a pathogenic BRCA mutation.2. Methods
Our family cancer clinic in the University Medical
Center Groningen provides genetic counselling and
screening to women who may carry a BRCA mutation
based on their personal and/or family history. If the
patient or family fulﬁls the Dutch criteria for genetic
testing, comprehensive BRCA1 and BRCA2 mutation
testing is performed in one or more index cases.17 Once
a pathogenic BRCA mutation has been detected, tar-
geted genetic testing for this mutation is oﬀered to all
relatives, using a cascade protocol.18
Information was collected up to March 2008 and pre-
viously used to calculate the breast and ovarian cancer
penetrance for BRCA mutation families3; this informa-
tion was updated upto September 2011 for the current
study. Data were retrieved from patients’ medical
records and entered into a separate, anonymous, pass-
word-protected database. Under the Dutch law, this
means no further approval from our institution’s Ethics
Review Board was needed.For all women, we collected information on the date
of birth and death or last contact, as well as data on the
familial gene mutation, their breast- and ovarian cancer
status, and if and when a risk-reducing mastectomy
(RRM) and/or RRSO had been performed. Data about
breast- and ovarian cancer in the general population was
obtained from the Dutch Comprehensive Cancer
Centre.19,20
All analyses were performed using PASW Statistics
18.0 software, and statistical signiﬁcance was deﬁned
as p < 0.05. Descriptive statistics were applied to analyse
patient characteristics, diﬀerences in continuous and cat-
egorical variables were tested two-sided with the Mann–
Whitney U-test and Fishers’ exact test, respectively.
Kaplan–Meier survival analyses were used to calculate
the cumulative incidence rates. To calculate the breast
cancer risk, right-censoring was applied at the age of
RRM (N = 1), the age at RRSO if performed before
the age of 50 (N = 4), at the last contact, or age at death.
In the ovarian cancer risk analyses, women were cen-
sored at the age at RRSO (N = 4), at the last contact,
or age at death. Standardised incidence ratios (SIRs)
were calculated for the age-speciﬁc breast cancer inci-
dence, both with and without stratiﬁcation by the BRCA
gene. The numbers of observed cases were compared
with the numbers of expected cases, which were calcu-
lated using data from the Dutch Comprehensive Cancer
Centre.19,20 To account for possible ascertainment bias,
SIRs were also calculated for the group of proven non-
carriers expanded with the group of non-tested women.
In unaﬀected women, the probability of testing negative
increases with advancing age, so we divided women into
10-year age groups that had diﬀerent probabilities of
being negative. The numbers in each age group were
multiplied by the probability of being negative and then
added together to obtain the estimated number that
would have tested negative.143. Results
In 365 BRCA-positive families (219 BRCA1 and 146
BRCA2 families), 1524 women were tested for a BRCA1
or BRCA2 mutation. Of these, 464 women tested nega-
tive for their family-speciﬁc BRCA mutation and were
included in this study. In total there were 700 untested
ﬁrst-degree female relatives of 20 years or older, of
whom 184 (26%) developed breast cancer.
With a mean age at last contact of 44.9 years for the
group of non-carriers, 17 women had been diagnosed
with breast cancer. Thirteen of these cases were among
283 non-carriers in BRCA1 families (one case was bilat-
eral) and four were among 181 non-carriers in BRCA2
families. For the 17 cases the mean age at diagnosis
was 46.5 years (standard deviation (SD) 7.0): 44.8 years
(SD 7.2) in BRCA1 families and 51.9 years (SD 2.9) in
BRCA2 families (p = 0.045). This mean age at diagnosis
Table 1
Cumulative incidence of breast and ovarian cancer among proven BRCA non-carriers and the general population.
Age (years) Breast cancer Ovarian cancer
Proven non-carriersa General population19 Proven non-carriersa General population19
40 1.3 (0.0–2.5) 0.6 0.0 (0.0–0.0) 0.1
50 6.4 (2.9–9.8) 2.5 0.4 (0.0–1.3) 0.1
60 9.5 (5.0–14) 5.2 1.4 (0.0–3.5) 0.4
a 95% conﬁdence interval shown in brackets.
Fig. 1. Cumulative incidence of breast cancer (A) and ovarian cancer (B) for non-carriers (with 95% conﬁdence interval) and age-matched women
from the general population.
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lation of 61.9 years (SD 14.3), but the diﬀerence was
not signiﬁcant (p = 0.17).3
Two cases of ovarian cancer had been detected, both
in non-carriers in BRCA1 families. Their ages at diagno-
sis were 43 and 55 years, which were much lower than
the mean age in the general population (65.5, SD 13.7).
The overall breast cancer risk for non-carriers in
BRCA2 families was lower than in BRCA1 families,
but this was not signiﬁcant (hazard ratio = 0.44 (95%
conﬁdence interval (CI) 0.14–1.35), p = 0.15). By the
age of 60, the non-carriers had a breast cancer risk of
9.5% (95% CI 5.0–14.1%), whereas women in the general
population had a risk of 5.2% (Table 1).19 At all ages,
the breast cancer risk was higher in the proven non-
carriers than in the age-matched cohort from the general
population (Fig. 1). By the age of 50 the breast cancer
risk was signiﬁcantly higher; the expected cumulative
incidence was outside the conﬁdence interval of the
observed cumulative incidence. The ovarian cancer risk
was slightly higher in non-carriers than in the gen-
eral population from age 50 upwards, but this was not
signiﬁcant (Table 1).
We compared the observed number of breast cancers
to the expected number of cases in the general popula-
tion (Table 2). There were signiﬁcantly more cases
observed in the non-carriers in BRCA1 families in the
age groups under 50 years: 30–39 years SIR 11 (95%
CI 3.0–29) and 40–49 years SIR 4.5 (95% CI 1.8–9.2).In non-carriers in BRCA2 families, the number of
observed cases was not signiﬁcantly higher than
expected. Except for the signiﬁcantly raised SIRs in
the BRCA2 group 40–49 years and the total BRCA
group, the SIRs did not change signiﬁcantly when the
calculation was based on non-carriers and a proportion
of the 700 women not tested (Table 2).
The 19 symptomatic non-carriers came from 14
BRCA1 and 4 BRCA2 families. In 204 BRCA families,
all the proven non-carriers were still so far free of breast
and/or ovarian cancer, while another 143 BRCA families
contained no known non-carriers. To assess the
diﬀerence in cancer incidence due to genetic modiﬁers
and/or environmental factors, we compared the relatives
in BRCA families with symptomatic non-carriers to
those families without symptomatic non-carriers
(Table 3). We observed no diﬀerences in the numbers
of cases or mean age at diagnosis, or in the cancer risk
for either all family members or for the carriers alone.
However, among the BRCA1 families, the number of
breast cancers was signiﬁcantly higher in families with
non-carriers diagnosed with breast cancer before the
age of 50 than in families with non-carriers aﬀected after
the age of 50, or in families with no aﬀected non-carriers.
4. Discussion
We investigated the occurrence of breast and ovarian
cancer in 464 proven non-carriers in BRCA families in a
Table 3
Family history of cancer in BRCA carriers and relatives at 50% risk but not tested, in families with and without aﬀected proven non-carriers.
BRCA familiesa BRCA1 familiesb
Relatives of aﬀected
non-carriers
N = 115
Relatives of only
non-aﬀected
non-carriers
N = 1174
P Relatives of aﬀected
non-carriers with
BC < 50 years
N = 75
Relatives of
(non-)aﬀected
non-carriers
N = 1214
P
Mean age (standard deviation, SD)
Breast cancer 46 (12) 45 (12) 0.45 45 (12.1) 43 (12) 0.41
Ovarian cancer 51 (11) 53 (12) 0.95 53 (12.0) 50(10) 0.29
Number (%)
Breast cancers 48 (42%) 417 (36%) 0.19 34 (47%) 264 (34%) 0.04
Ovarian cancers 21 (18%) 169 (14%) 0.34 15 (21%) 131 (17%) 0.42
Abbreviations: BC, breast cancer.
a Comparison of BRCA families with aﬀected proven non-carriers with a diagnosis of breast or ovarian cancer and families with only proven non-
carriers with no diagnosis of breast or ovarian cancer.
b Comparison of BRCA1 families with non-carriers with a breast cancer diagnosis before the age of 50, on the one hand, and BRCA1 families
with aﬀected non-carriers at over 50 and BRCA1 families with no aﬀected non-carriers, on the other hand.
Table 2
Standardised incidence ratios of breast cancer by BRCA gene and age groupa in (A) non-carriers and (B) non-carriers and assumed non-carriers.
Age BRCA1 BRCA2 BRCA total
Obs. Exp. SIR 95% CI Obs. Exp. SIR 95% CI Obs. Exp. SIR 95% CI
(A) Non-carriers
30–39 4 0.4 11 3.0–29 0 0.3 – – 4 0.6 6.4 1.7–16
40–49 7 1.6 4.5 1.8–9.2 2 0.9 2.1 0.3–7.6 9 2.6 3.5 1.6–6.7
50–59 2 2.6 0.8 0.1–2.8 2 1.8 1.2 0.1–4.4 4 4.5 0.9 0.2–2.3
Totalb 13 6.6 2.0 1.1–3.3 4 4.7 0.8 0.2–2.1 17 11.6 1.5 0.9–2.3
(B) Non-carriers and not-tested women
30–39 6.5 0.6 11 5.8–19 0.5 0.3 1.6 0.1–11 7 0.9 7.5 3.7–12
40–49 8.6 1.5 3.4 1.9–5.7 4.5 1.6 2.8 1.1–4.7 13 4.2 3.1 2.0–5.0
50–59 4 4.3 0.9 0.4–1.7 4 3.0 1.3 0.9–3.2 8 7.6 1.1 0.6–1.7
Totalb 19 11 1.7 1.0–2.5 9.1 8.3 1.1 0.7–1.9 28 20 1.4 1.0–2.0
Abbreviations: obs. observed; exp. expected; SIR standarised incidence ratio; CI conﬁdence interval.
a No breast cancers were observed after the age of 59 years.
b Ages: 20–69 years.
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ment. We show that the cumulative incidence of breast
cancer in proven non-carriers in their ﬁfth decade is
2.6 times higher than in the general population, with a
SIR of 3.5 (95% CI 1.6–6.7) and a mean age at diagnosis
that was 15 years earlier. This study is the ﬁrst to assess
ovarian cancer risks for proven non-carriers. Only two
cases were diagnosed at ages much younger than the
mean age at diagnosis in the general population.
Previously published estimates on breast cancer risk
in non-carriers in the BRCA families vary widely. We
found an increased cancer risk for proven non-carriers
at all ages compared with women from the general pop-
ulation. This is in line with three other clinic-based stud-
ies from England,14 Canada15 and Poland16 that
reported a signiﬁcantly increased risk of at least twofold.
However, four other studies (two clinic-based studies
from the United States8,9 and one from Australia,11
and one population-based study from the United
States10) report contradictory results that show thatthe risk of proven non-carriers is not increased or at
least not twice as high as in the general population. Pos-
sible explanations may be diﬀerences in: (1) ascertain-
ment, (2) study design, or (3) national screening
protocols.10 First, studies with ascertainment by a fam-
ily cancer clinic will probably result in higher risk esti-
mates, since families referred to these clinics have a
stronger history of breast cancer than the general popu-
lation. Second, although a prospective study design is
favored,27,28 it might result in lower risk estimates as a
substantial number of the family members have already
been diagnosed before visiting the family cancer clinic,
and non-symptomatic proven non-carriers are no longer
followed-up in such clinics. As an illustration, when we
applied left-censoring at the moment of the individual’s
DNA test, the follow-up time was short and only a few
breast cancer cases were observed in this period. Third,
countries with more stringent inclusion criteria for
genetic counselling or those in which additional screen-
ing for non-carriers is readily available will probably
J.R. Vos et al. / European Journal of Cancer 49 (2013) 2101–2106 2105show a larger risk diﬀerence between non-carriers in
proven BRCA families and the general population.21
The younger age of proven non-carriers at diagnosis
of breast cancer has not been discussed before. Their
mean age of breast cancer diagnosis (46.5 years, SD
7.0) is considerably lower than the mean age for the gen-
eral Dutch population (61.9 years, SD 14.3).3 This is
mainly due to the high number of diagnoses in non-car-
riers in BRCA1 families in the 30–39 and 40–49 year age
groups, resulting in SIRs of 11 and 4.5, respectively.
Other studies in non-carriers have reported mean ages
at diagnosis between 44.3 and 50.9 years.10,15,22 The dif-
ferent study approaches may explain the diﬀerences
found in the mean age at breast cancer diagnosis. The
ﬁgures we present here are based on a cohort study in
a family cancer clinic setting, which included all non-
carriers with a ﬁrst-degree relative carrying a BRCA
mutation. To date, the lowest mean age at diagnosis,
44.3 years, was reported in a clinic-based retrospective
cohort study that consisted of only Ashkenazi Jewish
families, which might explain the lower mean age at
diagnosis.22 The highest mean age at diagnosis, 50.9
years, was reported in a population-based study in
ﬁrst-degree relatives in BRCA-negative families, but it
also reported mean ages of 42.1 and 44.5 years in
BRCA1- and BRCA2-positive families, respectively.10
Recent large studies have shown that the genetic var-
iability in breast and ovarian cancer risks can be partly
explained by common modiﬁer alleles.14,23,24 Therefore,
it is likely that a residual increased risk of breast cancer
in proven non-carriers from BRCA families will be due
to the presence of other familial, predisposing low-risk
alleles and/or BRCA penetrance modiﬁers. We assumed
that in families with such penetrance-increasing
modiﬁers, the percentage of symptomatic mutation car-
riers and the percentage of bilateral cases would be
higher, and that their mean age at diagnosis would be
lower. We therefore compared these parameters between
the families with symptomatic non-carriers and the fam-
ilies with only non-symptomatic non-carriers and found
signiﬁcantly more cases of breast cancer in BRCA1 fam-
ilies with non-carriers diagnosed before the age of 50
than in all other BRCA1 families with proven non-carri-
ers. Future analyses of genetic modiﬁers and/or environ-
mental factors in our cohort may explain these ﬁndings,
but at the moment we have no overall explanation for
the increased risk seen in young non-carriers from
BRCA1 families.
Our study has various strengths, for example, its
design as a consecutive cohort with a uniform, clinic-
based ascertainment. We consider data obtained from -
non-carrier populations that are ascertained at family
cancer clinics to be diﬀerent to population-based data
and, as such, more applicable to the genetic counselling
setting. The women seen at the genetics clinics are the
ones to whom the screening policies are actually appliedand which are adapted according to their mutation sta-
tus. Our study is the ﬁrst to present an ovarian cancer
risk assessment for proven non-carriers and the low risk
ﬁgures appear to be reassuring.
Our study may have been aﬀected by several limita-
tions. First, it might be liable to recall bias because we
used information on the family history of cancer
reported by women during the course of regular care
at the family cancer clinic. However, cases were vali-
dated by hospital records or information was provided
by ﬁrst-degree relatives, who are known to report their
family cancer history accurately.25,26 If any bias is pres-
ent, we are more likely to have under- than overesti-
mated because relatives are more likely to under-
report than to over-report cancer. Second, our study
could be subject to ascertainment bias. Once a non-
symptomatic woman has tested negative, she is no
longer monitored in a high-risk screening program,
and BRCA2 families are less likely to be referred to a
family clinic because of the older mean age at diagnosis
of breast cancer. Both issues may lead to an under-
reporting of cancer and consequently underestimate
the cancer incidence in the study population and inﬂu-
ence the mean age at diagnosis. However, there was only
a minor signiﬁcant change in the SIRs in the total BRCA
group when ﬁrst-degree relatives who had not been
tested were included. Third, selection bias could play a
role since no proven non-carriers were known in 143
BRCA families. However, we observed no other diﬀer-
ences between these and the other BRCA families, so
we would expect any potential eﬀect to be small.
The results from our previous study3 and the current
analyses show that female non-carriers in BRCA fami-
lies are indeed at an increased risk of developing breast
cancer from age 40 onwards, which is in line with the
results of Smith et al.14 The number of observed cases
in non-carriers in the age 40–49 group is signiﬁcantly
increased: SIR 3.5 (95% CI 1.6–6.7). Their risk increase
is substantial and may justify starting screening from the
age of 40,29 rather than waiting for the national screen-
ing protocol which starts at the age of 50.30,31 The two
ovarian cancer cases occurred at an earlier age than seen
in the general population, but the very low incidence
means that there is no need for medical intervention.
Further research into lifestyle and genetic factors is
needed to explain the increased breast cancer risk seen
in proven BRCA non-carriers.Conﬂict of interest statement
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